One of the main advantages of the Russian vaccine from Coronavirus "Satellite V" is that with its high efficiency it does not require maintenance of ultra-low temperature during storage and transportation. So consider experts from American universities, familiar with the results of the third phase of clinical tests of the drug in The LanCet magazine.
Head of the Branch of Infectious Diseases at the Medical Faculty of Harvard University Daniel Kuritskis stressed that it is possible to store the Russian drug at a temperature provided by the usual refrigerator. He called it an advantage that will allow you to deliver a vaccine to those countries where less opportunities to provide its storage at ultra-low temperature.
The expert Tazhke noted that the level of protection that the Russian vaccine gives is not inferior to Pfizer and Moderna vaccines and higher than the drugs of Astrazeneca and Johnson & Johnson. In his opinion, "satellite V" can be one of those drugs that will put the end of the COVID-19 pandemic.
Infectiousness from the University of Georgia in Augusta Roger Makurtur said that the Russian development "looks very promising."
The infectious behalf of the Medical Center at Stanford University Din Winslow added that "satellite V" will play an important role in the fight against the pandemic. He also believes that for further strengthening confidence in the vaccine, it is possible to conduct its additional research.
Earlier, Russian scientists have published a report on the third phase of the test "Satellite V" in one of the most authoritative medical magazines in the world - British The Lancet. The article reported that the effectiveness of the vaccine is 91.6%, the level of antibodies after vaccination is almost 1.5 times higher than those who have surpassed coronavirus pneumonia. Antibodies were discovered in 98% of volunteers. Cell immunity was detected from all test participants. Of the 19,866 volunteers who received a vaccine during the tests were infected with only 78. Among volunteers, over 60 years of vaccine showed even more efficiency - 91.8%.
Based on: TASS.